Answers are grounded in this paper and cite their sources.
This editorial discusses the evolving role and clinical use of implantable cardioverter defibrillators in preventing sudden cardiac death in patients with left ventricular dysfunction.
Editorials18 March 2003The Clinical Use of Implantable Cardioverter Defibrillators: Where Are We Now? Where Should We Go?Alfred E. Buxton, MDAlfred E. Buxton, MDFrom Brown Medical School, Providence, Rhode Island.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-138-6-200303180-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Cardiovascular disease mortality continues to decline, but patients with left ventricular dysfunction, especially if it results from coronary artery disease, remain at high risk for both sudden and nonsudden death (1-4). In 1998, the latest year for which U.S. statistics are available, sudden cardiac death occurred in 456 076 persons, accounting for more than 60% of cardiac deaths (5). Overall, age-adjusted sudden death decreased 8.3% from 1989 to 1998. Sudden death decreased 11.7% in men, but only 5.8% in women; in fact, sudden death in women 35 to 44 years of age increased 21% over the 10-year period. The proportion ...References1. de Vreede JJ, Gorgels AP, Verstraaten GM, Vermeer F, Dassen WR, Wellens HJ. Did prognosis after acute myocardial infarction change during the past 30 years? A meta-analysis. J Am Coll Cardiol. 1991;18:698-706. [PMID: 1831213] CrossrefMedlineGoogle Scholar2. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, van Ree JW, Daemen MJ, Houben LG, et al. . Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol. 1997;30:1500-5. [PMID: 9362408] CrossrefMedlineGoogle Scholar3. Rouleau JL, Talajic M, Sussex B, Potvin L, Warnica W, Davies RF, et al. . Myocardial infarction patients in the 1990stheir risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) Study. J Am Coll Cardiol. 1996;27:1119-27. [PMID: 8609330] CrossrefMedlineGoogle Scholar4. Tavazzi L, Volpi A. Remarks about postinfarction prognosis in light of the experience with the Gruppo Italiano per lo Studio della Sopravvivenza n' nfarto Miocardico (GISSI) trials. Circulation. 1997;95:1341-5. [PMID: 9054869] CrossrefMedlineGoogle Scholar5. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation. 2001;104:2158-63. [PMID: 11684624] CrossrefMedlineGoogle Scholar6. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. . Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781-8. [PMID: 1900101] CrossrefMedlineGoogle Scholar7. Ezekowitz JA, Armstrong PW, McAlister FA. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med. 2003;138:445-52. LinkGoogle Scholar8. Buxton AE, Hafley GE, Lehmann MH, Gold M, O'Toole M, Tang A, et al. . Prediction of sustained ventricular tachycardia inducible by programmed stimulation in patients with coronary artery disease. Utility of clinical variables. Circulation. 1999;99:1843-50. [PMID: 10199881] CrossrefMedlineGoogle Scholar9. Domanski MJ, Sakseena S, Epstein AE, Hallstrom AP, Brodsky MA, Kim S, et al. . Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators. J Am Coll Cardiol. 1999;34:1090-5. [PMID: 10520795] MedlineGoogle Scholar10. Moss AJ, Fadl Y, Zareba W, Cannom DS, Hall WJ. Survival benefit with an implanted defibrillator in relation to mortality risk in chronic coronary heart disease. Am J Cardiol. 2001;88:516-20. [PMID: 11524060] CrossrefMedlineGoogle Scholar11. Bnsch D, Castrucci M, Bcker D, Breithardt G, Block M. Ventricular tachycardias above the initially programmed tachycardia detection interval in patients with implantable cardioverter-defibrillators: incidence, prediction and significance. J Am Coll Cardiol. 2000;36:557-65. [PMID: 10933372] CrossrefMedlineGoogle Scholar12. Freedberg NA, Hill JN, Fogel RI, Prystowsky EN. Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy: implications for antiarrhythmic therapy and driving restrictions. CARE Group. J Am Coll Cardiol. 2001;37:1910-5. [PMID: 11401131] CrossrefMedlineGoogle Scholar13. Epstein AE, Powell J, Yao Q, Ocampo C, Lancaster S, Rosenberg Y, et al. . In-hospital versus out-of-hospital presentation of life-threatening ventricular arrhythmias predicts survival: results from the AVID Registry. Antiarrhythmics Versus Implantable Defibrillators. J Am Coll Cardiol. 1999;34:1111-6. [PMID: 10520799] CrossrefMedlineGoogle Scholar14. Pires LA, Lehmann MH, Buxton AE, Hafley GE, Lee KL. Differences in inducibility and prognosis of in-hospital versus out-of-hospital identified nonsustained ventricular tachycardia in patients with coronary artery disease: clinical and trial design implications. J Am Coll Cardiol. 2001;38:1156-62. [PMID: 11583897] CrossrefMedlineGoogle Scholar15. Wyse DG, Friedman PL, Brodsky MA, Beckman KJ, Carlson MD, Curtis AB, et al. . Life-threatening ventricular arrhythmias due to transient or correctable causes: high risk for death in follow-up. J Am Coll Cardiol. 2001;38:1718-24. [PMID: 11704386] CrossrefMedlineGoogle Scholar16. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. . Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933-40. [PMID: 8960472] CrossrefMedlineGoogle Scholar17. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882-90. [PMID: 10601507] CrossrefMedlineGoogle Scholar18. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. . Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83. [PMID: 11907286] CrossrefMedlineGoogle Scholar19. Buxton AE, Lee KL, Hafley GE, Wyse DG, Fisher JD, Lehmann MH, et al. . Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the multicenter unsustained tachycardia trial. Circulation. 2002;106:2466-72. [PMID: 12417544] CrossrefMedlineGoogle Scholar20. Ruskin JN, Camm AJ, Zipes DP, Hallstrom AP, McGrory-Usset ME. Implantable cardioverter defibrillator utilization based on discharge diagnoses from Medicare and managed care patients. J Cardiovasc Electrophysiol. 2002;13:38-43. [PMID: 11843481] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Alfred E. Buxton, MDAffiliations: From Brown Medical School, Providence, Rhode Island.Corresponding Author: Alfred E. Buxton, MD, Brown Medical School, 2 Dudley Street, Suite 360, Providence, RI 02905. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoImplantable Cardioverter Defibrillators in Primary and Secondary Prevention Justin A. Ezekowitz , Paul W. Armstrong , and Finlay A. McAlister Metrics Cited byImplantable Cardioverter-DefibrillatorsElectrophysiological device therapy (implantable defibrillators) in older adultsIncreased rate of subacute lead complications with small-caliber implantable cardioverter-defibrillator leadsMarketing InnovationMedical device prices follow the experience curveIncreased incidence of subacute lead perforation noted with one implantable cardioverter-defibrillatorDrug Therapy for Ventricular Tachyarrhythmia in Heart FailurePrognostic Utility of Microvolt T-Wave Alternans in Risk Stratification of Patients With Ischemic CardiomyopathyImplantable Cardioverter‐Defibrillators for Secondary Prevention: Is It Worth It in the Elderly?ICD Therapy: What Have We Learned From the Clinical Trials?Microvolt T-Wave Alternans and the Risk of Death or Sustained Ventricular Arrhythmias in Patients With Left Ventricular DysfunctionCan Amiodarone Prevent Sudden Cardiac Death in Patients with Hemodynamically Tolerated Sustained Ventricular Tachycardia and Coronary Artery Disease?The Use of Implantable Cardioverter Defibrillators for the Prevention of Sudden Cardiac Death: A Review of the Evidence and ImplicationsK/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis PatientsPrediction of sudden cardiac death after acute myocardial infarction: role of Holter monitoring in the modern treatment eraInhibition of Unnecessary RV Pacing with AV Search Hysteresis in ICDs (INTRINSIC RV):. Design and Clinical ProtocolRevisiting the Biomedicalization of Aging: Clinical Trends and Ethical ChallengesTime Dependence of Mortality Risk and Defibrillator Benefit After Myocardial InfarctionEvolution of the Implantable Cardioverter DefibrillatorThe Evolution of the Implantable Cardioverter DefibrillatorNew Evidence from the Secondary Endpoints of the MADIT II StudyPost-infarction Patients with Left Ventricular Ejection Fraction of 30%-40%, Non-sustained Ventricular Tachycardia, and without Inducible Tachyarrhythmias: Is ICD Therapy Necessary?The patient with an implantable cardioverter defibrillatorRoutine Implantation of Cardioverter/Defibrillator Devices in Patients Aged 75 Years and Older With Prior Myocardial Infarction and Left Ventricular Ejection Fraction <30: Antagonist ViewpointMADIT II (Second Multicenter Automated Defibrillator Implantation Trial) DebateCost-Effectiveness of ICD Therapy in the Prevention of Sudden Death in CAD and/or HF Patients 18 March 2003Volume 138, Issue 6Page: 512-514KeywordsArrhythmiaCardiovascular therapyDeath ratesEjection fractionHeartImplantable cardioverter defibrillatorsMortalityMyocardial infarctionSudden cardiac deathVentricular tachycardia ePublished: 18 March 2003 Issue Published: 18 March 2003 Copyright & PermissionsCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
Alfred E. Buxton (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: